These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 16534469

  • 1. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
    Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E.
    Transplantation; 2006 Mar 15; 81(5):686-91. PubMed ID: 16534469
    [Abstract] [Full Text] [Related]

  • 2. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D.
    N Engl J Med; 2004 Feb 19; 350(8):767-76. PubMed ID: 14973216
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 19; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
    Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW.
    Endocr J; 2013 Sep 19; 60(2):167-72. PubMed ID: 23064476
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
    Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN.
    Transplantation; 2003 Nov 27; 76(10):1498-502. PubMed ID: 14657693
    [Abstract] [Full Text] [Related]

  • 7. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G.
    J Bone Miner Res; 2001 Nov 27; 16(11):2111-7. PubMed ID: 11697808
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ.
    J Bone Miner Res; 2006 Feb 27; 21(2):300-6. PubMed ID: 16418786
    [Abstract] [Full Text] [Related]

  • 9. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 27; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 27; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 11. Alendronate is effective to treat bone loss in renal transplantation recipients.
    Lan G, Peng L, Xie X, Peng F, Wang Y, Yu S.
    Transplant Proc; 2008 Dec 27; 40(10):3496-8. PubMed ID: 19100422
    [Abstract] [Full Text] [Related]

  • 12. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May 27; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 13. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct 27; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 14. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul 27; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 27; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 16. Bone loss after cardiac transplantation.
    Lindsay R.
    N Engl J Med; 2004 Feb 19; 350(8):751-4. PubMed ID: 14973219
    [No Abstract] [Full Text] [Related]

  • 17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 19; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 18. Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.
    White HD, Ahmad AM, Durham BH, Joshi AA, Fraser WD, Vora JP.
    J Clin Endocrinol Metab; 2011 Mar 19; 96(3):726-36. PubMed ID: 21252245
    [Abstract] [Full Text] [Related]

  • 19. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 19; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 20. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL, Resnick NM, Parker RA.
    J Clin Endocrinol Metab; 2005 May 19; 90(5):2762-7. PubMed ID: 15713726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.